The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | Lurbinectedin in combination with pembrolizumab in relapsed SCLC
Andrea Ardizzoni, MD, PhD, University of Bologna, Bologna, Italy, shares findings from the LUPER study (NCT04358237) which aimed to explore the efficacy and safety of combining lurbinectedin with pembrolizumab in the second-line treatment of recurrent small cell lung cancer. The combination demonstrated efficacy with manageable safety, suggesting its potential as a second-line therapy for SCLC and warranting further exploration. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
